MR
Mersana Therapeutics, Inc.
MRSN · NASDAQ
$29.74 +2.42% (+$0.70)
Market Cap $145.2M
P/E Ratio -
Div. Yield -
ROE 183.15%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
41 /100
Fair P/S 4.38x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing Rev. growth 880.21%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak FCF margin 224.14%
Op. margin 203.06%
Gross margin 99.14%
Quality
37 /100
Average Asset turnover 0.53x
ROA 111.80%
ROIC 310.35%
Debt
60 /100
Moderate Int. coverage -24.52x
Net debt/EBITDA 0.82x
Current ratio 1.39x
Stability
37 /100
Moderate Profitable years 0
EPS volatility 26.22%
Beta 0.43x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MRSN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Martin H. Huber
Employees
102
Headquarters
Cambridge